Using Synbiotics as a Therapy to Protect Mental Health in Alzheimer's Disease

키워드

참고문헌 (86)

1. Srivastava S, "Alzheimer’s disease and its treatment by different approaches : a review", Eur. J. Med. Chem, 216, pp.113320~ (2021)
2. Haghighat N, "The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis : a double-blind, randomized, placebocontrolled trial", Indian J. Nephrol, 31, pp.149~ (2021)
3. Talebi M, "Nutraceuticals-based therapeutic approach : recent advances to combat pathogenesis of Alzheimer’s disease", Exp. Rev. Neurother, 21, pp.625~642 (2021)
4. DeCarolis NA, "Hippocampal neurogenesis as a target for the treatment of mental illness : a critical evaluation", Neuropharmacology, 58, pp.884~893 (2010)
5. Ravetz RS, "Psychiatric disorders associated with Alzheimer’s disease", J. Am. Osteopath. Assoc, 99, pp.S13~S16 (1999)
6. Mendez MF, "The relationship between anxiety and Alzheimer’s disease1", J. Alzheimer’s Disease Rep, 5, pp.171~177 (2021)
7. Knopman DS, "Alzheimer disease", Nat. Rev. Dis. Primers, 7, pp.33~ (2021)
8. Gibson GR, "Dietary modulation of the human colonic microbiota : updating the concept of prebiotics", Nutr. Res. Rev, 17, pp.259~275 (2004)
9. Dinan TG, "Psychobiotics : a novel class of psychotropic", Biol. Psychiatry, 74, pp.720~726 (2013)
10. Cheng L, "Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders", J. Food Drug Anal, 27, pp.632~648 (2019)
11. Lustbader JW, "ABAD directly links ASS to mitochondrial toxicity in Alzheimer’s disease", Science, 304, pp.448~452 (2004)
12. Hunt D, "Synaptic plasticity of NMDA receptors : mechanisms and functional implications", Curr. Opin. Neurobiol, 22, pp.496~508 (2012)
13. Vergara C, "Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo", Acta Neuropathol, 137, pp.397~412 (2019)
14. Bertram L, "Thirty years of Alzheimer’s disease genetics : the implications of systematic meta-analyses", Nat. Rev. Neurosci, 9, pp.768~778 (2008)
15. Shen J, "The presenilin hypothesis of Alzheimer’s disease : evidence for a loss-of-function pathogenic mechanism", Proc. Natl. Acad. Sci. USA, 104, pp.403~409 (2007)
16. Michalicová A, "TAU protein and its role in blood-brain barrier dysfunction", Front. Mol. Neurosci, 13, pp.570045~ (2020)
17. Medeiros R, "The role of TAU in Alzheimer’s disease and related disorders", CNS Neurosci. Ther, 17, pp.514~524 (2011)
18. Iqbal K, "Tau in Alzheimer disease and related tauopathies", Curr. Alzheimer Res, 7, pp.656~664 (2010)
19. Budimir A, "Metal ions, Alzheimer’s disease and chelation therapy", Acta Pharm, 61, pp.1~14 (2011)
20. Nita M, "The role of the reactive oxygen species and oxidative stress in the pathomechanism of the Age-Related ocular diseases and other pathologies of the anterior and posterior eye segments in adults", Oxid. Med. Cell. Longevity, 2016, pp.1~23 (2016)
21. Zhao Y, "Oxidative stress and the pathogenesis of Alzheimer’s disease", Oxid. Med. Cell. Longev, 2013, pp.1~10 (2013)
22. Guglielmotto, "Oxidative stress mediates the pathogenic effect of different Alzheimer’s disease risk factors", Front. Aging Neurosci (2010)[DOI]
23. Fan L, "New insights into the pathogenesis of Alzheimer’s disease", Front. Neurol, 10, pp.1312~ (2020)
24. Haque MdM, "Crosstalk between oxidative stress and tauopathy", Int. J. Mol. Sci, 20, pp.1959~ (2019)
25. Martin CR, "The brain-gut-microbiome axis", Cell. Mol. Gastroenterol. Hepatol, 6, pp.133~148 (2018)
26. Carabotti M, "The gut-brain axis : interactions between enteric microbiota, central and enteric nervous systems", Ann. Gastroenterol, 28, pp.203~209 (2015)
27. Morais LH, "The gut microbiota-brain axis in behaviour and brain disorders", Nat. Rev. Microbiol, 19, pp.241~255 (2020)
28. Schroeder FA, "Antidepressant-Like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse", Biol. Psych, 62, pp.55~64 (2007)
29. Frost G, "The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism", Nat. Commun, 5, pp.3611~ (2014)
30. Louveau A, "Structural and functional features of central nervous system lymphatic vessels", Nature, 523, pp.337~341 (2015)
31. Yoo BH, "The enteric network : interactions between the immune and nervous systems of the gut", Immunity, 46, pp.910~926 (2017)
32. Morimoto K, "Role of the immune system in the development of the central nervous system", Front. Neurosci, 13, pp.916~ (2019)
33. Ortega SB, "B cells migrate into remote brain areas and support neurogenesis and functional recovery after focal stroke in mice", Proc. Natl. Acad. Sci. USA, 117, pp.4983~4993 (2020)
34. Erny D, "Host microbiota constantly control maturation and function of microglia in the CNS", Nat. Neurosci, 18, pp.965~977 (2015)
35. Mukherjee S, "Gut microbes as future therapeutics in treating inflammatory and infectious diseases : lessons from recent findings", J. Nutr. Biochem, 61, pp.111~128 (2018)
36. Bonfili L, "Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels", Sci. Rep, 7, pp.2426~ (2017)
37. Archie SR, "Blood-brain barrier dysfunction in CNS disorders and putative therapeutic targets : an overview", Pharmaceutics, 13, pp.1779~ (2021)
38. Kobayashi Y, "Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease", Sci. Rep, 7, pp.13510~ (2017)
39. Kobayashi Y, "Effects of Bifidobacterium breve A1 on the cognitive function of older adults with memory complaints : a randomised, double-blind, placebo-controlled trial", Benef. Microbes, 10, pp.511~520 (2019)
40. Han D, "Prebiotics regulation of intestinal microbiota attenuates cognitive dysfunction induced by surgery stimulation in APP", PS1 mice, 2020, pp.11, 1029~
41. Arora K, "The microbiome and Alzheimer’s disease : potential and limitations of prebiotic, synbiotic, and probiotic formulations", Front. Bioeng. Biotechnol, 8, pp.537847~ (2020)
42. Pistollato F, "Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease : a focus on human studies", Pharmacol. Res, 131, pp.32~43 (2018)
43. Chen D, "Prebiotic effect of fructooligosaccharides from morinda officinalis on Alzheimer’s disease in rodent models by targeting the microbiota-gut-brain axis", Front. Aging Neurosci, 9, pp.403~ (2017)
44. Pasinetti GM, "Synbiotic-derived metabolites reduce neuroinflammatory symptoms of Alzheimer’s disease", Curr. Dev. Nutr, 4, pp.nzaa062_035~ (2020)
45. Wang W, "Lactobacillus plantarum 69-2 Combined with galacto-oligosaccharides alleviates d-galactose-induced aging by regulating the AMPK", SIRT1 signaling pathway and gut microbiota in mice, 2021, pp.69, 2745~2757
46. Westfall S, "A novel synbiotic delays Alzheimer’s disease onset via combinatorial gut-brain-axis signaling in Drosophila melanogaster", PLoS One, 14, pp.e0214985~ (2019)
47. Chunchai T, "Decreased microglial activation through gut-brain axis by prebiotics, probiotics, or synbiotics effectively restored cognitive function in obese-insulin resistant rats", J. Neuroinflammation, 15, pp.11~ (2018)
48. Patel C, "Potentiation of anti-Alzheimer activity of curcumin by probiotic Lactobacillus rhamnosus UBLR-58 against scopolamine-induced memory impairment in mice", Naunyn-Schmiedeberg’s Arch. Pharmacol, 393, pp.1955~1962 (2020)
49. Deng S, "The beneficial effect of synbiotics consumption on Alzheimer’s disease mouse model via reducing local and systemic inflammation", IUBMB Life, 74, pp.748~753 (2021)
50. Tamtaji OR, "Probiotic and selenium cosupplementation, and the effects on clinical, metabolic and genetic status in Alzheimer’s disease : a randomized, double-blind, controlled trial", Clin. Nutr, 38, pp.2569~2575 (2019)
51. Ton AMM, "Oxidative stress and dementia in Alzheimer’s patients : effects of synbiotic supplementation", Oxid. Med. Cell. Longev, 2020, pp.2638703~ (2020)
52. Haghighat N, "Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients : a randomized, double-blinded, clinical trial", Nutr. Neurosci, 24, pp.490~499 (2019)
53. Su F, "Inflammatory cytokines and Alzheimer’s disease : a review from the perspective of genetic polymorphisms", Neurosci. Bull, 32, pp.469~480 (2016)
54. Garcez ML, "Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid β(1-42)in mice", Prog. Neuropsychopharmacol. Biol. Psychiatry, 77, pp.23~31 (2017)
55. Selkoe DJ, "The amyloid hypothesis of Alzheimer’s disease at 25 years", EMBO Mol. Med, 8, pp.595~608 (2016)
56. Quintanilla RA, "Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5", p35 pathway, 2004, pp.295, 245~257
57. Khoury JE, "CD36 mediates the innate host response to Β-Amyloid", J. Exper. Med, 197, pp.1657~1666 (2003)
58. Chellappa RC, "G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer’s disease pathology", PLoS One, 15, pp.e0225487~ (2020)
59. Janelsins MC, "Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTG-AD mice", Am. J. Pathol, 173, pp.1768~1782 (2008)
60. McAlpine FE, "Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology", Neurobiol. Dis, 34, pp.163~177 (2009)
61. Berg JV, "Inhibition of IL-12", IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline, 2012, pp.18, 1812~1819
62. Liu L, "IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population", Int. J. Cancer, 128, pp.1692~1696 (2011)
63. Halder N, "Cholinergic system and its therapeutic importance in inflammation and autoimmunity", Front. Immunol, 12, pp.660342~ (2021)
64. Shah S, "Novel osmotin inhibits SREBP2 via the AdipoR1", AMPK, Mol. Psychiatry, pp.2016, 22[DOI]
65. Assefa BT, "The bewildering effect of AMPK activators in Alzheimer’s disease : review of the current evidence", BioMed Res. Int, 2020, pp.9895121~ (2020)
66. Zhang M, "Therapeutic potential of natural molecules against Alzheimer’s disease via SIRT1 modulation", Biomed. Pharmacother, 161, pp.114474~ (2023)
67. Manoharan S, "The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease : a mini review", Oxid. Med. Cell. Longev, 2016, pp.8590578~ (2016)
68. Oliver D, "Small molecules as therapeutic drugs for Alzheimer’s disease", Mol. Cell. Neurosci, 96, pp.47~62 (2019)
69. Drake J, "Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid β-peptide(1-42)in a transgenic Caenorhabditis elegans model", Neurobiol. Aging, 24, pp.415~420 (2003)
70. Laske C, "BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls", J. Psychiatr. Res, 41, pp.387~394 (2007)
71. Mori Y, "Serum BDNF as a potential biomarker of Alzheimer’s disease : verification through assessment of serum, cerebrospinal fluid, and medial temporal lobe atrophy", Front. Neurol, 12, pp.653267~ (2021)
72. Zilberter Y, "The vicious circle of hypometabolism in neurodegenerative diseases : ways and mechanisms of metabolic correction", J. Neurosci. Res, 95, pp.2217~2235 (2017)
73. Yılmaz A, "Diagnostic biomarkers of Alzheimer’s disease as identified in saliva using 1H NMR-based metabolomics", J. Alzheimer’s disease, 58, pp.355~359 (2017)
74. Cui M, "Metabolomics and incident dementia in older Chinese adults : the Shanghai aging study", Alzheimers Dement, 16, pp.779~788 (2020)
75. Ho L, "Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer’s disease-type beta-amyloid neuropathological mechanisms", Exp. Rev. Neurother, 18, pp.83~90 (2017)
76. Fernando WMADB, "Sodium butyrate reduces brain amyloid-Β levels and improves cognitive memory performance in an Alzheimer’s disease transgenic mouse model at an early disease stage", J. Alzheimer’s Dis, 74, pp.91~99 (2020)
77. Filippone A, "Protective effect of sodium propionate in Aβ1-42-induced neurotoxicity and spinal cord trauma", Neuropharmacology, 166, pp.107977~ (2020)
78. Westfall S, "A novel polyphenolic prebiotic and probiotic formulation have synergistic effects on the gut microbiota influencing Drosophila melanogaster physiology", Artif. Cells Nanomed. Biotechnol, 46, pp.441~455 (2018)
79. Ownby RL, "Depression and risk for Alzheimer disease", Arch. Gen. Psych, 63, pp.530~ (2006)
80. Methiwala HN, "Gut microbiota in mental health and depression : role of pre", pro, Food Funct, pp.2021, 12[DOI]
81. Ayichew T, "Bacterial probiotics their importances and limitations: a review", J. Nutr. Health Sci, 4 (2017)[DOI]
82. Dudek-Wicher R, "Clinical trials of probiotic strains in selected disease entities", Int. J. Microbiol, 2020, pp.8854119~ (2020)
83. Zmora N, "Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features", Cell, 174, pp.1388~1405 (2018)
84. Suez J, "The pros, cons, and many unknowns of probiotics", Nat. Med, 25, pp.716~729 (2019)
85. Boyer EW, "The serotonin syndrome", New Engl. J. Med, 352, pp.1112~1120 (2005)
86. Lee YS, "Prebiotic lactulose ameliorates the cognitive deficit in Alzheimer’s disease mouse model through macroautophagy and chaperone-mediated autophagy pathways", J. Agric. Food Chem, 69, pp.2422~2437 (2021)

관련 논문AI추천